Towards HCV extinction with modern HCV treatment? “Yes we can !”
With the availability of new drugs (Directly Acting Antivirals, DAA), the ambition to eradicate HCV infection even in patients infected by “difficult-to-treat” genotypes is becoming a reality. Benefits are enormous from an individual and a global perspective since about 3% people in the world are chronically infected, with a burden of 350,000 deaths related to the long-term complications of the disease (cirrhosis and hepato-cellular carcinoma).
The lessons we learned from HIV treatment (Highly Active Antiretroviral Therapy, HAART) are that antivirals pay-off by saving costs of clinical complications, patients’ stress and sufferance, and an increase in productivity of the infected individuals can be achieved for the sake of the society. Moreover, control of HIV replication induced by HAART can reduce the infection burden in the general population by decreasing HIV transmissibility . This is extremely important for infection control when coupled with behavioural interventions since for
- Cohen MS, Chen YQ, McCauley M, et al.: Prevention of HIV-1 infection with early antiretroviral therapy. New England Journal of Medicine 2011, 365:493–505. CrossRef
- Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F: Chronic HCV infection: epidemiological and clinical relevance. BMC Infectious Diseases 2012,12(Suppl 2):S2.
- Petta S, Craxì A: Therapeutic algorithms for chronic hepatitis C in the DAA era during the current economic crisis: whom to treat? How to treat? When to treat? BMC Infectious Diseases 2012,12(Suppl 2):S3.
- Nucara S, Caroleo B, Guadagnino V, Perrotti N, Trapasso F: Natural history and clinical response: “It’s the virus, stupid, or is it the host?”. BMC Infectious Diseases 2012,12(Suppl 2):S6.
- Colucci G: Molecular diagnostic and predictive tests in the evolution of chronic hepatitis C anti-viral therapies. BMC Infectious Diseases 2012,12(Suppl 2):S8. CrossRef
- Lo Re V, Amorosa VK, Localio AR, et al.: Adherence to hepatitis C virus therapy and early virologic outcomes. Clinical Infectious Diseases 2009, 48:186–193. CrossRef
- Liberto MC, Marascio N, Zicca E, Matera G: Epidemiological features and specificities of HCV infection: a hospital-based cohort study in a University Medical Center of Calabria region. BMC Infectious Diseases 2012,12(Suppl 2):S4. CrossRef
- Ciccozzi M, Lo Presti A, Ciccaglione AR, Zehender G, Ciotti M: Phylogeny and phylodinamic of Hepatitis C in Italy. BMC Infectious Diseases 2012,12(Suppl 2):S5. CrossRef
- Puoti M, Rossotti R, Travi G, Orso M, Moioli MC: Top topics in HCV research arena. BMC Infectious Diseases 2012,12(Suppl 2):S7.
- Torti C, Zazzi M, Abenavoli L, Trapasso F, Cesario F, Corigliano M, Cosco L, Costa C, Curia RL, De Rosa M, Foti G, Giraldi C, Leone R, Liberto MC, Lucchino D, Marascio N, Masciari R, Matera G, Pisani V, Serrao N, Surace L, Zicca E, Castelli F, Ciccozzi M, Puoti M, Focà A, SINERGIE Study Group: Future research and collaboration: the “SINERGIE” project on HCV. BMC Infectious Diseases 2012,12(Suppl 2):S9. CrossRef
- Towards HCV extinction with modern HCV treatment? “Yes we can !”
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
BMC Infectious Diseases
- Online Date
- November 2012
- Online ISSN
- BioMed Central
- Additional Links